Only systemic treatment for relapsed or refractory (r/r) CTCL to target the IL-2 receptor on malignant T-cells and Tregs LYMPHIR is expected to launch within the next five months LYMPHIR's approval ...

A collaborative research group led by Haruna Kimura (graduate student), Dr. Akito Hasegawa (Assistant Professor), and Prof. Riichiro Abe from the Division of Dermatology, Niigata University Graduate ...

Please provide your email address to receive an email when new articles are posted on . Cutaneous adverse events with GLP-1 receptor agonists are rare but can include rash and pruritus. Clinicians ...

Lymphir, an immunotherapy, has been approved by the FDA to treat patients with relapsed or refractory cutaneous T-cell lymphoma. The Food and Drug Administration has approved Lymphir (denileukin ...

The human epidermal growth factor receptor (HER1/EGFR) is dysregulated in many solid tumors, making it an attractive target for anticancer therapy. A number of agents that target this receptor are in ...

LYMPHIR targets cancerous T-cells with an IL-2 receptor-directed fusion protein, showing a 36.2% objective response rate in phase 3 trials. The therapy provides rapid relief from severe pruritus and ...

Niigata, Japan - A collaborative research group led by Haruna Kimura (graduate student), Dr. Akito Hasegawa (Assistant Professor), and Prof. Riichiro Abe from the Division of Dermatology, Niigata ...

Lung and bronchus cancer in young females: Exploring sex disparities across diverse racial and ethnic groups in the U.S. (2000-2020). This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting ...